Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Urogen Pharma (URGN : NSDQ)
 
 • Company Description   
UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel.

Number of Employees: 195

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.61 Daily Weekly Monthly
20 Day Moving Average: 173,350 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta: 1.41
52 Week High: $19.66
52 Week Low: $5.25
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.54% -10.51%
12 Week -5.24% 4.17%
Year To Date -41.01% -29.21%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
400 Alexander Park
-
Princeton,NJ 08540
USA
ph: 646-768-9780
fax: -
vincent.perrone@urogen.com http://www.urogen.com
 
 • General Corporate Information   
Officers
Elizabeth Barrett - Chief Executive Officer
Arie Belldegrun - Chairman
Molly Henderson - Chief Financial Officer
Cynthia Butitta - Director
Fred E. Cohen - Director

Peer Information
Urogen Pharma (CORR.)
Urogen Pharma (RSPI)
Urogen Pharma (CGXP)
Urogen Pharma (BGEN)
Urogen Pharma (GTBP)
Urogen Pharma (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: M96088105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta: 1.41
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.32 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.81 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -6.84%
vs. Previous Quarter: 1.57%
Sales Growth
vs. Year Ago Period: 81.22%
vs. Previous Quarter: -16.14%
ROE
03/31/22 - -572.49
12/31/21 - -256.66
09/30/21 - -173.25
ROA
03/31/22 - -78.96
12/31/21 - -87.69
09/30/21 - -88.93
Current Ratio
03/31/22 - 8.41
12/31/21 - 5.11
09/30/21 - 6.32
Quick Ratio
03/31/22 - 8.16
12/31/21 - 4.90
09/30/21 - 6.13
Operating Margin
03/31/22 - -209.30
12/31/21 - -230.67
09/30/21 - -283.41
Net Margin
03/31/22 - -209.30
12/31/21 - -230.67
09/30/21 - -283.41
Pre-Tax Margin
03/31/22 - -206.02
12/31/21 - -227.66
09/30/21 - -274.16
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - -
Inventory Turnover
03/31/22 - 1.38
12/31/21 - 1.34
09/30/21 - 1.35
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©